Abstract
Purpose
T cell receptor excision circle (TREC) quantification is a recent addition to newborn screening (NBS) programs and is intended to identify infants with severe combined immunodeficiencies (SCID). However, other primary immunodeficiency diseases (PID) have also been identified as the result of TREC screening. We recently reported a newborn with a low TREC level on day 1 of life who was diagnosed with WHIM (warts, hypogammaglobulinemia, infections, myelokathexis) syndrome, a non-SCID primary immunodeficiency caused by mutations in the chemokine receptor CXCR4.
Methods
We have now retrospectively reviewed the birth and clinical histories of all known WHIM infants born after the implementation of NBS for SCID.
Results
We identified six infants with confirmed WHIM syndrome who also had TREC quantification on NBS. Three of the six WHIM infants had low TREC levels on NBS. All six patients were lymphopenic but only one infant had a T cell count below 1,500 cells/μL. The most common clinical manifestation was viral bronchiolitis requiring hospitalization. One infant died of complications related to Tetralogy of Fallot, a known WHIM phenotype.
Conclusion
The results suggest that WHIM syndrome should be considered in the differential diagnosis of newborns with low NBS TREC levels.
Trial Registration
Not applicable.
Similar content being viewed by others
Change history
28 January 2021
A Correction to this paper has been published: https://doi.org/10.1007/s10875-021-00976-x
Abbreviations
- ALC:
-
Absolute lymphocyte count
- ANC:
-
Absolute neutrophil count
- CD:
-
Cluster of differentiation
- Ct:
-
Cycle threshold number
- CXCR4:
-
C-X-C chemokine receptor type 4
- DOL:
-
Day of life
- G-CSF:
-
Granulocyte colony-stimulating factor
- IgRT:
-
Immunoglobulin replacement therapy
- m:
-
Month
- mcg:
-
Microgram
- ml:
-
Milliliter
- NBS:
-
Newborn screen
- NICU:
-
Neonatal intensive care unit
- PID:
-
Primary immunodeficiency
- RTEs:
-
Recent thymic emigrants
- SCID:
-
Severe combined immunodeficiency
- TRECs:
-
T cell receptor excision circles
- WBC:
-
White blood count
- WGS:
-
Whole-genome sequencing
- WHIM:
-
Warts, hypogammaglobulinemia, infections, myelokathexis
- y:
-
Year
References
Beaussant Cohen S, Fenneteau O, Plouvier E, et al. Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet J Rare Dis. 2012;7:71 Published 2012 Sep 25.
Aghamohammadi A, Abolhassani H, Puchalka J, Greif-Kohistani N, Zoghi S, Klein C, et al. Preference of genetic diagnosis of CXCR4 mutation compared with clinical diagnosis of WHIM syndrome. J Clin Immunol. 2017;37(3):282–6.
Heusinkveld LE, Majumdar S, Gao JL, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56. https://doi.org/10.1007/s10875-019-00665-w.
Evans MO 2nd, McDermott DH, Murphy PM, Petersen MM. Abnormal newborn screen in a WHIM syndrome infant. J Clin Immunol. 2019;39(8):839–41. https://doi.org/10.1007/s10875-019-00686-5.
Mentzer WC, Johnston RB, Baehner RL, Nathan DG. An unusual form of chronic neutropenia in a father and daughter with hypogammaglobulinaemia. Br J Haematol. 1977;36:313–22.
Amatuni G, Currier R, Church J, Bishop T, Grimbacher E, Nguyen A, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California, 2010-2017. Pediatrics. 2019;143:2.
Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States [published correction appears in JAMA. 2014 Nov 26;312(20):2169. Bonagura, Vincent R [added]]. JAMA. 2014;312(7):729–38.
Gans MD, Gavrilova T. Retrospective analysis of a New York newborn screen severe combined immunodeficiency referral center. J Clin Immunol. 2020;40(3):456–65.
Dotta L, Notarangelo L, Moratto D, Kumar R, Porta F, Soresina A, et al. Long-term outcome of WHIM syndrome in 18 patients: high risk of lung disease and HPV-related malignancies. J Allergy Clin Immunol Pract. 2019;7(5):1568–77.
Balabanian K, Brotin E, Biajoux V, Bouchet-Delbos L, Lainey E, Fenneteau O, et al. Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice. Blood. 2012;119(24):5722–30. https://doi.org/10.1182/blood-2012-01-403378.
Gul KA, Strand J, Pettersen RD, Brun H, Abrahamsen TG. T-cell receptor excision circles in newborns with heart defects. Pediatr Cardiol. 2020;41(4):809–15. https://doi.org/10.1007/s00246-020-02317-y.
Gul KA, Øverland T, Osnes L, Baumbusch LO, Pettersen RD, Lima K, et al. Neonatal levels of T-cell receptor excision circles (TREC) in patients with 22q11.2 deletion syndrome and later disease features. J Clin Immunol. 2015;35(4):408–15. https://doi.org/10.1007/s10875-015-0153-5.
van der Spek J, Groenwold RH, van der Burg M, van Montfrans JM. TREC based newborn screening for severe combined immunodeficiency disease: a systematic review. J Clin Immunol. 2015;35(4):416–30.
Patrawala M, Kobrynski L. Nonsevere combined immunodeficiency T-cell lymphopenia identified through newborn screening. Curr Opin Allergy Clin Immunol. 2019;19(6):586–93. https://doi.org/10.1097/ACI.0000000000000586.
Barry JC, Crowley TB, Jyonouchi S, Heimall J, Zackai EH, Sullivan KE, et al. Identification of 22q11.2 deletion syndrome via newborn screening for severe combined immunodeficiency. J Clin Immunol. 2017;37(5):476–85. https://doi.org/10.1007/s10875-017-0403-9.
Albin-Leeds S, Ochoa J, Mehta H, Vogel BH, Caggana M, Bonagura V, et al. Idiopathic T cell lymphopenia identified in New York state newborn screening. Clin Immunol. 2017;183:36–40. https://doi.org/10.1016/j.clim.2017.07.002.
Trampont PC, Tosello-Trampont AC, Shen Y, Duley AK, Sutherland AE, Bender TP, et al. CXCR4 acts as a costimulator during thymic beta-selection. Nat Immunol. 2010;11(2):162–70. https://doi.org/10.1038/ni.1830.
Chatterjee S, Behnam Azad B, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82. https://doi.org/10.1016/B978-0-12-411638-2.00002-1.
Poulain S, Roumier C, Venet-Caillault A, Figeac M, Herbaux C, Marot G, et al. Genomic landscape of CXCR4 mutations in Waldenström Macroglobulinemia. Clin Cancer Res. 2016;22(6):1480–8. https://doi.org/10.1158/1078-0432.CCR-15-0646.
Kawai T, Malech HL. WHIM syndrome: congenital immune deficiency disease. Curr Opin Hematol. 2009;16(1):20–6.
Funding
This work was supported in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA (Grant# AI000615–28), National Institute of Allergy and Infectious Diseases, National Institutes of Health-funded CXCR4 gene sequencing and clinical encounters for multiple patients.
Author information
Authors and Affiliations
Contributions
M.E., M.P., D.M., A.K., S.J., Y.K., J.C., and D.M. provided medical care for the patients. M.E., M.P., D.M., A.K., S.J., Y.K., J.C., D.M., P.M., G.E., and J.W. assisted with data gathering. M.E., G.E., J.C., A.K., and S.J. spoke with state newborn screening labs. S.M. performed mice studies as well as manuscript editing. M.E., M.P., P.M., and D.M. wrote the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Three patients were enrolled in the National Institutes of Health (NIH) study 14-I-0185. Informed consent was obtained and all data appropriately de-identified. Three other patients were enrolled in an IRB-approved protocol at the University of South Florida and Johns Hopkins All Children’s Hospital (USF) that allowed collection of data on patients with WHIM syndrome from collaborating sites. NIH and USF contributed this de-identified data for joint analysis and publication.
Conflict of Interest
J.E.W. has received grants as principal investigator on investigator-initiated translational studies and sponsored clinical trials of patients with WHIM syndrome funded by X4 Pharmaceuticals.
Unrelated:
J.E.W. has been an advisory board member, speaker bureau participant and site-principal investigator for a trial funded by Takeda (former Shire) outside of the submitted work.
J.E.W. has also run sponsored studies for Lediant, Octapharma, and Momenta as site principal investigator outside of the submitted work.
Consent to Participate
Freely-given, informed consent to participate in the study was obtained from parent or legal guardians for each infant.
Consent for Publication
Consent from individuals to publish de-identified data was included in NIH and USF enrollment consents.
Disclaimer
The views expressed in this article are those of the author and do not reflect the official policy or position of the Department of the Army, DOD, or the U.S. Government.
Code Availability
Not applicable.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original online version of this article was revised: It contained errors in Tables 1 and 3.
Rights and permissions
About this article
Cite this article
Evans, M.O., Petersen, M.M., Khojah, A. et al. TREC Screening for WHIM Syndrome. J Clin Immunol 41, 621–628 (2021). https://doi.org/10.1007/s10875-020-00921-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-020-00921-4